Eidos Therapeutics, Inc. announced it raised $26 Million in an initial filing from an offering of $74 Million

Apr 12, 2018•about 7 years ago

Amount Raised

$26 Million

San FranciscoBiotechnology

Company Information

Company

Eidos Therapeutics, Inc.

Location

101 MONTGOMERY STREET, SUITE 2550

San Francisco, California, United States

About

Targeting TTR amyloidosis at its source. Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs.

Medium Activity

Get personalized insights on buying likelihood

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech